Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
33307,"Takeda Development Center Americas, Inc.",IL,100000000338,59.00,11/21/2013,"Cash or cash equivalent",106112524,"","","Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events","",""
